Showing results (1-10 of 44) with videos related to
Sort By:
Pageof 5
Nature Reviews. Clinical Oncology|July 19, 2020
Publisher Correction: The adenosine pathway in immuno-oncologyBertrand Allard, David Allard, Laurence Buisseret, et al.Nature Reviews. Clinical Oncology|June 10, 2020
The adenosine pathway in immuno-oncologyBertrand Allard, David Allard, Laurence Buisseret, et al.Trends in Cancer|July 14, 2026
Neoadjuvant immunotherapy in breast cancer: Progress and challengesManon de Graaf, Alex De Caluwé, Laurence Buisseret, et al.Seminars in Oncology|September 11, 2020
Management of early breast cancer in patients bearing germline BRCA mutationsMarie-Daphné t'Kint de Roodenbeke, Noam Pondé, Laurence Buisseret, et al.BMJ Case Reports|September 21, 2011
Optic neuropathy, renal failure and pulmonary sarcoidosis in a 50-year-old man: where is the link?Laurence Buisseret, Nacima Kisma, Annick Massart, et al.ESMO Open|November 28, 2017
Targeting immune checkpoints in breast cancer: an update of early resultsCinzia Solinas, Andrea Gombos, Sofiya Latifyan, et al.Oncoimmunology|August 16, 2019
Adenosine A2a receptor promotes lymphangiogenesis and lymph node metastasisBertrand Allard, Isabelle Cousineau, David Allard, et al.Cancer Research|November 23, 2016
PolyI:C and CpG Synergize with Anti-ErbB2 mAb for Treatment of Breast Tumors Resistant to Immune Checkpoint InhibitorsRoxanne Charlebois, Bertrand Allard, David Allard, et al.Cold Spring Harbor Molecular Case Studies|March 2, 2023
<i>PIK3CA</i> copy-number gain and inhibitors of the PI3K/AKT/mTOR pathway in triple-negative breast cancerOttavia Amato, Laurence Buisseret, Géraldine Gebhart, et al.Current Opinion in Oncology|August 21, 2025
Immunotherapy in the neoadjuvant treatment of hormone receptor-positive/HER2-negative early breast cancer: novel approaches and future perspectivesLuca Arecco, Gabriella Gentile, Riccardo Gerosa, et al.Pageof 5